Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeed Innov Regulatory News (SEED)

Share Price Information for Seed Innov (SEED)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.20
Bid: 4.00
Ask: 4.20
Change: -0.05 (-1.20%)
Spread: 0.20 (5.00%)
Open: 4.15
High: 4.15
Low: 4.10
Prev. Close: 4.10
SEED Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Investee Company Update: Yooma Wellness

Tue, 27th Jul 2021 07:00

RNS Number : 5250G
Seed Innovations Limited
27 July 2021


Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

27 July 2021

SEED Innovations Limited ("SEED" or the "Company") 

Investee Company Update: Yooma Wellness

SEED Innovations Limited, the AIM quoted company focusing on making investments in fast growing and industry leading businesses with a focus on investing within the medical cannabis, health and wellness space, is pleased to note the announcement by its portfolio company, Yooma Wellness Inc. ('Yooma'), in which it holds a 5.1% interest, that it has secured subscriptions for its latest financing round of US$9.7 million* and will submit an application for admission of its common shares to trading on the AQSE Growth Market.

* Conditional upon admission to trading on the AQSE Growth Market


The announcement by Yooma is set out below without material changes or adjustments:

TORONTO, July 26, 2021 /PRNewswire/ - Yooma Wellness Inc. ("Yooma" or the "Company") (CSE: YOOM), a global vertically integrated wellness platform that develops and markets a portfolio of CBD and wellness brands, is pleased to announce it has secured subscriptions for its latest financing round and will submit an application for the admission of its common shares to trading on the U.K.'s AQSE Growth Market ("AQSE"). The financing is expected to be completed and trading to commence on August 10, 2021, at which time Yooma's shares, which are already listed on the Canadian Securities Exchange, will be dual-listed on the AQSE. 

Yooma, together with its European deal coordinator, Chrystal Capital Partners LLP, has raised gross proceeds of US$9.7 million, or approximately GBP £7.1 million, through the placing of 13,504,301 Common Shares ("Placing Shares"), at a price of C$0.90 (£0.5232) per share (the "Placing Price"). Investors have also been granted a half warrant for each Placing Share subscribed for ("Warrants") with each Warrant exercisable at a price of C$1.35 (£0.7849) per Common Share, and which expire on the third anniversary of listing on the AQSE. In aggregate Yooma has granted investors a total of 6,752,139 Warrants.

Yooma has also granted a single strategic investor ("Strategic Investor") an option ("Option") to acquire 9,555,555 Common Shares at the Placing Price, that will raise an additional £5 million gross proceeds for the Company if exercised, which would bring the total amount raised in the financing to US$16.6 million (£12.1 million). Subject to exercise of the Option, the Strategic Investor will be granted 4,777,777 Warrants on the same basis as the other investors. The Option has been granted to September 17, 2021, due to delays in the Strategic Investor setting up its proposed holding structure for the investment. The Company is however satisfied that due diligence has been completed by such party and the additional time will allow administrative arrangements to be completed prior to an investment of £5 million.

In connection with the financing, Yooma will also pay aggregate cash commissions of US$236,724 and grant 219,189 non-transferrable warrants to certain eligible persons who provided finance and investor introduction services in connection with the financing, with an exercise price of C$0.90 per share and a term of two years from the date of listing on the AQSE. 

"We are pleased to be announcing this financing, including the addition of many UK and European based shareholders, which will allow Yooma to continue its rapid growth through strategic acquisitions," said Lorne Abony, Chairman of Yooma. "Once the Option has been exercised the financing will be oversubscribed, which will accelerate Yooma's growth and quest to become a global leader in the CBD and wellness space."

Yooma has also announced the appointment of Simon Dryan to the board of directors. Mr. Dryan will join as an independent non-executive director and brings over 35 years of UK industry experience in investment banking and other financial-related industries. Mr. Dryan was previously the head of the equity division at Rock Investments, a large U.K. investment fund. He also has over 25 years of experience in global equity markets, spending time as the Director of European Equities at Merrill Lynch, as well as holding positions at Smith NewCourt and Lehman Brothers. 

Certain directors of Yooma will acquire Common Shares and Warrants in the financing. Such participation will be considered a "related party transaction" for the purposes of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company intends to rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a), as the aggregate fair market value of the consideration for the related party transaction, insofar as it involves interested parties, does not exceed 25% of the issuer's market capitalization. The Company did not file a material change report in respect of the financing 21 days before the anticipated completion of the financing, which the Company deems reasonable in the circumstances in order to complete the financing expeditiously and concurrently with the Company's anticipated listing on the AQSE. 

About Yooma Wellness Inc.Yooma's mission is to build a vertically-integrated global leader in the manufacturing, marketing, distribution, and sale of wellness products including hemp seed oil and hemp-derived and cannabinoid (CBD) ingredients. The company leverages strategically curated sales channels and ecommerce networks to deliver a diverse mix of wellness products through operating subsidiaries in the United States, United Kingdom, France and Japan. Learn more at

Media Contact:Michael BancroftEmail:

Issuer Contact:Jordan Greenberg Email:

 For further information on the Company please visit or contact:

-Ends -

Ed McDermott /

Lance de Jersey

SEED Innovations Ltd



James Biddle /

Roland Cornish

Beaumont Cornish Limited,



Tel: +44 (0) 207 628 3396

Isabella Pierre /

Damon Heath

Shard Capital Partners LLP


T: +44 (0)20 7186 9927

Catherine Leftley /

Isabel de Salis

St Brides Partners Ltd,

Financial PR





SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
9th Aug 20227:00 amRNSNotice of AGM & Investor Presentation
8th Aug 20227:00 amRNSFurther Investment in South West Brands Limited
1st Aug 20227:00 amRNSNew Investment: Clean Food Group Ltd
21st Jul 20227:00 amRNSFinal Results
12th Jul 202212:10 pmRNSInvestee Company Update: Little Green Pharma Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.